Nektar Therapeutics (NKTR)

Dec 15, 2025

Nektar Therapeutics (Nasdaq: NKTR) to review 36-week REZOLVE-AA topline data Dec. 16 - Stock Titan

Dec 15, 2025

Dec 14, 2025

Transformative Advances This Year and Beyond - Dermatology Times

Dec 14, 2025

Dec 13, 2025

Nektar Therapeutics (NASDAQ:NKTR) Stock Price Up 11%Here's Why - MarketBeat

Dec 13, 2025

Dec 13, 2025

Rezpegaldesleukin Shows Promise for AD, Comorbid Asthma, With Jonathan Corren, MD - HCPLive

Dec 13, 2025

Dec 13, 2025

Published on: 2025-12-14 04:41:07 - moha.gov.vn

Dec 13, 2025

Dec 12, 2025

Nektar Therapeutics (NASDAQ:NKTR) Trading Down 5.5%Here's What Happened - MarketBeat

Dec 12, 2025

Dec 12, 2025

Nektar Therapeutics (NASDAQ:NKTR) Shares Down 5.5%What's Next? - MarketBeat

Dec 12, 2025

Dec 11, 2025

Nektar Therapeutics’ Earnings Call Highlights Robust Growth and Innovation - MSN

Dec 11, 2025

Dec 09, 2025

Can Nektar Therapeutics Stock Recover If Markets Fall? - Trefis

Dec 09, 2025

Dec 08, 2025

Here's Why Nektar Therapeutics (NKTR) is a Great Momentum Stock to Buy - sharewise.com

Dec 08, 2025

Dec 08, 2025

Nektar Therapeutics $NKTR Shares Sold by 22NW LP - MarketBeat

Dec 08, 2025

Dec 07, 2025

Is Nektar Therapeutics (NKTR) Still Undervalued After Its Recent Share Price Rebound? - Yahoo Finance

Dec 07, 2025

Dec 05, 2025

Nektar Therapeutics gains amid takeover speculation - MSN

Dec 05, 2025

Dec 05, 2025

Nektar Therapeutics (NKTR) Price Target Increased by 14.31% to 109.43 - Nasdaq

Dec 05, 2025

Dec 05, 2025

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus

Dec 05, 2025

Dec 05, 2025

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire

Dec 05, 2025

Dec 05, 2025

Stonepine Capital Management LLC Makes New Investment in Nektar Therapeutics $NKTR - MarketBeat

Dec 05, 2025

Dec 05, 2025

Nektar Therapeutics (NASDAQ:NKTR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Dec 05, 2025

Dec 04, 2025

Citi Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $102 - 富途牛牛

Dec 04, 2025

Dec 04, 2025

Will Nektar Therapeutics stock maintain dividend yieldOptions Play & Real-Time Volume Trigger Notifications - Newser

Dec 04, 2025

Dec 04, 2025

Can Nektar Therapeutics (ITH0) stock stage a strong rebound this quarterPortfolio Performance Summary & Weekly High Return Stock Opportunities - Newser

Dec 04, 2025

Dec 04, 2025

Will Nektar Therapeutics stock benefit from green energy trendsTrade Signal Summary & Daily Oversold Stock Bounce Ideas - Newser

Dec 04, 2025

Dec 04, 2025

How robust is Nektar Therapeutics (ITH0) stock financial positionAnalyst Upgrade & Risk Controlled Daily Trade Plans - Newser

Dec 04, 2025

Dec 04, 2025

How strong dollar benefits Nektar Therapeutics (ITH0) stockTrade Risk Assessment & Long-Term Safe Investment Ideas - Newser

Dec 04, 2025

Dec 03, 2025

NKTR SEC FilingsNektar Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan

Dec 03, 2025

Dec 03, 2025

Will Nektar Therapeutics stock benefit from upcoming earnings reports2025 Top Gainers & Verified Momentum Stock Alerts - Newser

Dec 03, 2025

Dec 03, 2025

Is Nektar Therapeutics stock attractive for ETFs2025 Winners & Losers & Long-Term Growth Stock Strategies - Newser

Dec 03, 2025

Dec 03, 2025

Nektar Therapeutics Data from REZOLVE-AD Study Accepted for Late-Breaking Oral Presentation - MSN

Dec 03, 2025

Dec 02, 2025

Nektar Therapeutics (NASDAQ:NKTR) Shares Down 7.5%What's Next? - MarketBeat

Dec 02, 2025

Dec 02, 2025

Colorectal Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | Takeda, Genentech/Seagen, AstraZeneca and Daiichi Sankyo, Merck, Amgen, Daiichi Sankyo Company, Mirati Therapeu - Barchart.com

Dec 02, 2025

Dec 02, 2025

ADARx Pharmaceuticals Appoints Mary Tagliaferri, M.D., to its Board of Directors - The Manila Times

Dec 02, 2025

Dec 02, 2025

ADARx Pharmaceuticals Appoints Mary Tagliaferri, M.D., to its Board of Directors - GlobeNewswire Inc.

Dec 02, 2025

Dec 02, 2025

Latex Allergy Market Covering Prime Factors and Competitive - openPR.com

Dec 02, 2025

Dec 01, 2025

Wall Street Analysts Believe Nektar (NKTR) Could Rally 64.53%: Here's is How to Trade - Finviz

Dec 01, 2025

Nov 29, 2025

Nektar Therapeutics Reveals Promising Phase 2b Trial Results - MSN

Nov 29, 2025

Nov 28, 2025

Nektar Therapeutics (NKTR) Stock Forecasts - Yahoo Finance

Nov 28, 2025

Nov 27, 2025

Nektar Therapeutics (NASDAQ:NKTR) Shares Gap UpShould You Buy? - MarketBeat

Nov 27, 2025

Nov 26, 2025

Nektar Therapeutics Reports Second Quarter 2025 Financial Results (PR Newswire) - Aktiellt

Nov 26, 2025

Nov 26, 2025

Jefferies Maintains Nektar Therapeutics (NKTR) Buy Recommendation - Nasdaq

Nov 26, 2025

Nov 26, 2025

Citigroup Initiates Coverage on NKTR with 'Buy' Rating | NKTR St - GuruFocus

Nov 26, 2025

Nov 26, 2025

Jefferies Raises Nektar Therapeutics (NKTR) Price Target to $121 - GuruFocus

Nov 26, 2025

Nov 26, 2025

Nektar Therapeutics R (ITH0.MU) Q2 FY2025 earnings call transcript - Yahoo Finance

Nov 26, 2025

Nov 26, 2025

Nektar Therapeutics CEO sells $119,795 in shares By Investing.com - Investing.com South Africa

Nov 26, 2025

Nov 26, 2025

Citi starts Nektar with Buy, opens ‘positive catalyst watch’ - TipRanks

Nov 26, 2025

Nov 26, 2025

Nektar (NKTR) Receives Buy Rating with Positive Outlook from Cit - GuruFocus

Nov 26, 2025

Nov 26, 2025

Citi Initiates Nektar Therapeutics(NKTR.US) With Buy Rating, Announces Target Price $102 - 富途牛牛

Nov 26, 2025

Nov 26, 2025

Portland Topic NEKTAR THERAPEUTICS | News, Weather, Sports, Breaking News - KATU

Nov 26, 2025

Nov 26, 2025

Jefferies Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Raises Target Price to $121 - 富途牛牛

Nov 26, 2025

Nov 26, 2025

Nektar Therapeutics chief R&D officer sells $62,801 in stock By Investing.com - Investing.com Australia

Nov 26, 2025

Nov 25, 2025

Nektar Therapeutics CLO Wilson sells $34,196 in shares By Investing.com - Investing.com South Africa

Nov 25, 2025

Nov 25, 2025

Nektar Therapeutics Announces Pricing of $100 Million Public Offering (PR Newswire) - Aktiellt

Nov 25, 2025

Nov 25, 2025

Nektar Therapeutics chief R&D officer sells $62,801 in stock - Investing.com

Nov 25, 2025

Nov 25, 2025

Nektar Therapeutics CLO Wilson sells $34,196 in shares - Investing.com

Nov 25, 2025